|1.||Rodgers, R J: 4 articles (04/2013 - 03/2004)|
|2.||Upton, N: 4 articles (11/2005 - 03/2004)|
|3.||Ishii, Y: 4 articles (11/2005 - 03/2004)|
|4.||Halford, J C G: 3 articles (05/2005 - 03/2004)|
|5.||Blundell, J E: 3 articles (05/2005 - 03/2004)|
|6.||Porter, R: 3 articles (05/2005 - 03/2004)|
|7.||Johns, A: 3 articles (05/2005 - 03/2004)|
|8.||Li, Aihua: 2 articles (01/2010 - 05/2009)|
|9.||Dias, Mirela Barros: 2 articles (01/2010 - 05/2009)|
|10.||Kotz, C M: 1 article (01/2014)|
02/28/2005 - "The present studies were designed to test the hypothesis that the inhibition of weight gain following acute treatment with SB-334867 is due to a persistent anorectic action of the compound. "
05/07/2005 - "50 min) had no significant impact on the anorectic, behavioural or weight gain effects of SB-334867 in non-deprived male rats. "
03/15/2002 - "In this study, the anti-obesity effects of SB-334867-A were determined in genetically obese (ob/ob) mice dosed with SB-334867-A (30 mg/kg, i.p.) once daily for 7 days, and then twice daily for a further 7 days. "
01/03/2014 - "The OX1R antagonist, SB-334867-A, and the DA1R antagonist, SCH3390, in SN more effectively reduced SPA stimulated by OXA in obesity-resistant rats. "
|3.||Body Weight (Weight, Body)
11/01/2005 - "Body weight was also reduced in OM rats 1d after injection of SB-334867 but not in the S5B rats. "
11/01/2005 - "Ad libitum fed rats were injected intraperitoneally with SB-334867 at doses of 3, 10 or 30 mg/kg, or vehicle at the beginning of the dark cycle, and food intake and body weight were measured. "
03/15/2002 - "SB-334867-A reduced cumulative food intake and body weight gain over 14 days. "
09/01/2010 - "SB-334867-A and SNAP-7941 significantly increased BAT temperature and UCP1 expression and reduced food intake and body weight. "
|4.||Weight Loss (Weight Reduction)
03/01/2004 - "Furthermore, whereas LiCl failed to alter posttreatment bodyweight gain, SB-334867 (30 mg/kg) produced a significant weight loss in the 24-h period immediately following injection. "
02/28/2005 - "Anorexia and weight loss in male rats 24 h following single dose treatment with orexin-1 receptor antagonist SB-334867."
|5.||Hypoglycemia (Reactive Hypoglycemia)
04/01/2007 - "SB-334867 treatment prior to acute NPH administration decreased plasma glucose and suppressed peak glucagon secretion, whereas exogenous ORX-A administration prior to RIIH did not reverse amplified patterns of hypoglycemia. "
04/01/2004 - "Microinjection of the orexin-A receptor antagonist SB-334867 into the dorsal motor nucleus of the vagus (DMV) inhibited pancreatic nerve firing evoked by insulin-induced hypoglycemia by 56%. "
|4.||Asp(5)- oxytocin (OXA)
|5.||Risperidone (Risperdal Consta)